A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2636074
The invention relates to the combined use of anti-EGFR antibodies and anti- Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody "trastuzumab" (HERCEPTIN~) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody "matuzumab" (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
La présente invention concerne l'utilisation combinée d'anticorps anti-EGFR et d'anticorps anti-Her2 dans le traitement du cancer, particulièrement adaptée à un cancer exprimant des niveaux élevés du type EGFR et des niveaux faibles de HER2. La présente invention concerne en particulier l'anticorps monoclonal 'trastuzumab' (HERCEPTIN®) dirigé contre les récepteurs HER2, dont l'efficacité peut être significativement augmentée in vivo lorsqu'il est combiné à l'anticorps monoclonal 'matuzumab' (hmAB 425, EMD 72000) dirigé contre les récepteurs EGF. Le traitement combinatoire est adapté à des patients souffrant de cancers ayant ledit profil de récepteurs, préférentiellement des cancers du pancréas.
Azria David
Gillies Stephen D.
Larbouret Christel
Pelegrin Andre
Centre Regional de Lutte Contre Le Cancer
Fetherstonhaugh & Co.
L'institut National de La Sante Et de La Recherche Medicale
Merck Patent Gesellschaft Mit Beschraenkter Haftung
University Of Montpellier 1
LandOfFree
Combination therapy using anti-egfr and anti-her2 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy using anti-egfr and anti-her2 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using anti-egfr and anti-her2 antibodies will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1453777